Abbott (NYSE:ABT) said today that it logged a reimbursement win in Japan for its MitraClip device for treating mitral valve regurgitation.
The Chicago-area medtech giant said Japan’s Ministry of Health, Labor & Welfare granted national reimbursement for MitraClip, effective April 1. The MHLW approved the device last November for treating severe degenerative mitral regurgitation functional mitral regurgitation.
“Our mission is to develop technologies and therapies that help people return to better health and quality-of-life as quickly as possible,” structural heart VP Michael Dale said in prepared remarks. “With this reimbursement in Japan, we can help more people live better by reducing the severity of an extremely life-altering illness in a safe and predictable way.”
MitraClip won pre-market approval from the FDA in October 2013.
